Big Cypress Acquisition Corp.

Completed 2021-10-22
  • CIK 1833214
  • BCYP
  • Now SABS
  • IPO 2021-01-12
  • $116M trust
  • 436 filings

Successfully merged with SAB Biotherapeutics, Inc. • Now trading as SABS

IPO Size
$115M
raised at the IPO
Trust
$116M
as of 2021-09-30
Current Status
Completed
from its latest filing
IPO Year
2021
year it listed

Filings, by quarter

436 filings over 25 quarters; violet bars carry a milestone

  1. 20 Q4: 2 filings
  2. 21 Q1: 24 filings
  3. 21 Q2: 9 filings
  4. 21 Q3: 32 filings
  5. 21 Q4: 63 filings
  6. 22 Q1: 15 filings
  7. 22 Q2: 14 filings
  8. 22 Q3: 19 filings
  9. 22 Q4: 12 filings
  10. 23 Q1: 23 filings
  11. 23 Q2: 23 filings
  12. 23 Q3: 14 filings
  13. 23 Q4: 37 filings
  14. 24 Q1: 18 filings
  15. 24 Q2: 10 filings
  16. 24 Q3: 15 filings
  17. 24 Q4: 3 filings
  18. 25 Q1: 4 filings
  19. 25 Q2: 4 filings
  20. 25 Q3: 22 filings
  21. 25 Q4: 19 filings
  22. 26 Q1: 26 filings
  23. 26 Q2: 10 filings
  24. 26 Q3: 12 filings
  25. 26 Q4: 6 filings
  • S-1 filed 20 Q4
  • IPO 21 Q1
  • Definitive agreement 21 Q2
  • Completed 21 Q4

SPAC Overview

Where it stands on the road from S-1 to merger

Timeline Progress

About

Big Cypress Acquisition Corp. is a blank-check company seeking a business combination; it intends to focus on life science companies in the United States and Israel.

Investment Focus

Biopharmaceuticals

Geographic Focus

United States, Israel

Key Information

As the filings state it

IPO Date
2021-01-12
Total Redemptions
$81.1M
Jurisdiction of Incorporation
Delaware
SIC
6770
Completion Date
2021-10-22
Merger Target
SAB Biotherapeutics, Inc.
SPAC Ticker
BCYP
Merged Ticker
SABS

Stock Performance

SABS

Trading symbol, and its price at each step since the first trade

Stock performance
PointDatePriceMove
First Trade2021-02-09$10.22
At Merger2021-10-25$7.30-29%
6 Months Post-Merger2022-04-25$2.66-64%
1 Year Post-Merger2022-10-24$0.76-90%
2 Years Post-Merger2023-10-23$0.97-87%
Current Price2026-11-18$3.20-69%

SPAC Team

The banks on its IPO, and the team as the filings describe it

Underwriters

Extended Team Information

The management team reports more than 150 years of combined experience operating and investing in life science companies, and has collectively closed more than 50 mergers and acquisitions.

External Resources